User profiles for Isabelle Ray-Coquard
 | Isabelle Ray-CoquardCentre Leon Berard & Universite Claude Bernard Lyon I Verified email at lyon.unicancer.fr Cited by 51829 |
Volasertib versus chemotherapy in platinum-resistant or-refractory ovarian cancer: a randomized phase II Groupe des Investigateurs Nationaux pour l'Etude des …
…, F Selle, B Weber, IL Ray-Coquard… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic
arrest and apoptosis by targeting Polo-like kinase. This phase II trial evaluated volasertib or …
arrest and apoptosis by targeting Polo-like kinase. This phase II trial evaluated volasertib or …
[HTML][HTML] Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les …
M Penel-Page, I Ray-Coquard, J Larcade, M Girodet… - BMC cancer, 2015 - Springer
Background The objective of this study is to explore the off-label use of targeted therapies (TTs)
for patients with osteosarcoma registered within the French Sarcoma Group – Bone …
for patients with osteosarcoma registered within the French Sarcoma Group – Bone …
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical …
…, D Olive, S Perez, N Pasqual, C Faure, I Ray-Coquard… - Cancer research, 2009 - AACR
Immunohistochemical analysis of FOXP3 in primary breast tumors showed that a high number
of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the …
of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the …
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 …
…, E Pujade‐Lauraine, P Harter, I Ray‐Coquard… - Cancer, 2009 - Wiley Online Library
BACKGROUND: Primary surgery followed by platinum‐taxane based chemotherapy has
been the standard therapy in advanced ovarian cancer. However, the prognostic role of …
been the standard therapy in advanced ovarian cancer. However, the prognostic role of …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, P Harter, K Fujiwara, I Ray-Coquard… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
Dendritic cell infiltration and prognosis of early stage breast cancer
…, JY Blay, N Bendriss-Vermare, I Ray-Coquard… - Clinical Cancer …, 2004 - AACR
Purpose: Although dendritic cells (DC) and T cells can infiltrate primary breast carcinoma, it
remains unclear whether the immune response influences the clinical outcome. …
remains unclear whether the immune response influences the clinical outcome. …
[HTML][HTML] Lenvatinib plus pembrolizumab for advanced endometrial cancer
…, S Pignata, S Baron-Hay, I Ray-Coquard… - … England Journal of …, 2022 - Mass Medical Soc
Background Standard therapy for advanced endometrial cancer after failure of platinum-based
chemotherapy remains unclear. Methods In this phase 3 trial, we randomly assigned, in a …
chemotherapy remains unclear. Methods In this phase 3 trial, we randomly assigned, in a …
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
…, P Follana, D Bollag, I Ray-Coquard - Obstetrical & …, 2014 - journals.lww.com
Standard therapy for platinum-resistant ovarian cancer (OC) is single-agent chemotherapy.
The most active single agents are pegylated liposomal doxorubicin, paclitaxel, and topotecan…
The most active single agents are pegylated liposomal doxorubicin, paclitaxel, and topotecan…
[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
…, JM Cragun, A Oaknin, I Ray-Coquard… - The lancet …, 2017 - thelancet.com
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
